Chennai, March 18 Agilisium, a life sciences domain-specific AI services company, has invested ₹50 crore to help pharmaceutical, biotech, and medical technology companies operationalize artificial intelligence, a company official said on Wednesday.
Under this initiative, Agilisium has introduced Forward Deployment Experts (FDX) – a new professional standard built across four dimensions: AI, technology, consulting solutions, and process thinking.
According to a statement issued by the city-based company, the investment would reskill and deploy Agilisium's global workforce of over 1,000 professionals as embedded AI transformation partners.
Unlike a traditional consulting model, Agilisium's forward-deployment model combines deep Life Sciences domain expertise with AI engineering and data science capabilities.
Agilisium professionals work alongside scientists, clinical teams, and commercial stakeholders, designing and deploying, and continuously operating AI-driven capabilities.
Commenting on the occasion, Agilisium Founder and CEO Raj Babu said, "The biggest constraint in AI adoption in Life Sciences is no longer technology; it is talent. The companies that will lead Life Sciences in the next decade will not be the ones that simply purchase AI models. They will be the ones that embed AI capability deep inside their organizations."
He continued, "At Agilisium, our advantage comes from the institutional and domain knowledge we have built by focusing exclusively on Life Sciences."